Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
RNA Splicing Defects Contribute to Neurodegeneration in Alzheimer Disease, Model Suggests
10/26/2022
RNA splicing machinery dysfunction may cause neuronal excitatory toxicity and, thus, cognitive impairment in Alzheimer disease.
RNA splicing machinery dysfunction may cause neuronal excitatory toxicity and, thus, cognitive impairment in Alzheimer disease.
RNA splicing machinery...
10/26/2022
Psych Congress Network

Advertisement

News
Reboxetine Prescribed Alone Reduces Sleep Apnea Severity
10/25/2022
Reboxetine prescribed alone can reduce the severity of obstructive sleep apnea (OSA), according to new findings published in the Journal of Clinical Sleep Medicine.
Reboxetine prescribed alone can reduce the severity of obstructive sleep apnea (OSA), according to new findings published in the Journal of Clinical Sleep Medicine.
Reboxetine prescribed alone can...
10/25/2022
Neurology
From DepressionCare360
Adjunctive D-Cycloserine Improves Efficacy of Brain Stimulation in Patients with MDD
10/17/2022
Adding D-cycloserine to intermittent TBS significantly improved outcomes in patients with MDD.
Adding D-cycloserine to intermittent TBS significantly improved outcomes in patients with MDD.
Adding D-cycloserine to...
10/17/2022
Psych Congress Network
News
Investigational Oral Agent Significantly Reduces Alzheimer Disease Biomarkers
10/14/2022
After 12 months of treatment with investigational oral agent ALZ-801 (valiltramiprosate), patients with early Alzheimer disease demonstrated statistically significant and clinically relevant plasma biomarker reduction.
After 12 months of treatment with investigational oral agent ALZ-801 (valiltramiprosate), patients with early Alzheimer disease demonstrated statistically significant and clinically relevant plasma biomarker reduction.
After 12 months of treatment...
10/14/2022
Neurology

Advertisement

News
Dementia Diagnosis Associated With Increased Suicide Risk in Certain Subgroups
10/13/2022
The association was found in patients under 65 years, recently diagnosed, and those with psychiatric comorbidities.
The association was found in patients under 65 years, recently diagnosed, and those with psychiatric comorbidities.
The association was found in...
10/13/2022
Psych Congress Network
News
Eli-Cel Gene Therapy Approved for Early, Active Cerebral Adrenoleukodystrophy
10/12/2022
The FDA granted accelerated approval to elivaldogene autotemcel, also known as eli-cel (Skysona), to slow the progression of neurologic dysfunction in boys 4 through 17 years of age with early, active cerebral adrenoleukodystrophy (CALD).
The FDA granted accelerated approval to elivaldogene autotemcel, also known as eli-cel (Skysona), to slow the progression of neurologic dysfunction in boys 4 through 17 years of age with early, active cerebral adrenoleukodystrophy (CALD).
The FDA granted accelerated...
10/12/2022
Neurology
News
Neuromodulation Shown to Improve Memory in Older Adults
10/05/2022
Treatment with a combination of anatomical location and rhythmic frequency showed the most promise.
Treatment with a combination of anatomical location and rhythmic frequency showed the most promise.
Treatment with a combination of...
10/05/2022
Psych Congress Network

Advertisement

News
Acupuncture Improves Anxiety in Parkinson Disease Patients
10/03/2022
Acupuncture with clinical monitoring effectively eased anxiety in patients living with Parkinson disease, according to a study published online in JAMA Network Open. “Anxiety is closely associated with the accelerated progression of...
Acupuncture with clinical monitoring effectively eased anxiety in patients living with Parkinson disease, according to a study published online in JAMA Network Open. “Anxiety is closely associated with the accelerated progression of...
Acupuncture with clinical...
10/03/2022
Neurology
News
New ALS Drug Gets OK From FDA, Despite Lingering Efficacy Concerns
09/30/2022
On Thursday, the US Food and Drug Administration (FDA) approved sodium phenylbutyrate/taurursodiol (Relyvrio) to treat patients living with amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s disease.
On Thursday, the US Food and Drug Administration (FDA) approved sodium phenylbutyrate/taurursodiol (Relyvrio) to treat patients living with amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s disease.
On Thursday, the US Food and...
09/30/2022
Neurology
News
Smoking Causes Worse Outcomes After Ischemic Stroke, Gene Study Finds
09/29/2022
A genetic predisposition to smoking increases the risk of worse recovery from ischemic stroke, according to study results published online ahead of print in Neurology. “Our results provide genetic support for the theory that smoking causes...
A genetic predisposition to smoking increases the risk of worse recovery from ischemic stroke, according to study results published online ahead of print in Neurology. “Our results provide genetic support for the theory that smoking causes...
A genetic predisposition to...
09/29/2022
Neurology

Advertisement

Advertisement

Advertisement

News

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use